期刊文献+

在药品申报中关于包装系统研究内容的探讨 被引量:4

Discussion on container closure system for drug application
原文传递
导出
摘要 通过分析药品包装系统的作用和我国药用包装材料的管理状况,探讨在药品通用技术文件格式申报中需提供的相关研究内容,及药品研发过程中根据风险程度对包装材料和药品进行相容性研究。 To analyze the role of container closure system and the drug packaging materials management in China, this assay discussed the required research contents to be provided in the common technical documents(CTD) format and how to study the compatibility of packaging terial and drug products according to different risk levels in the proce drug development. mass of
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2012年第8期629-632,共4页 The Chinese Journal of Clinical Pharmacology
关键词 药品 包装材料 相容性 通用技术文件 包装系统 drug packaging material compatibility common technicaldocuments container closure system
  • 相关文献

参考文献5

  • 1M4 : The common technical document, Module 3 [ EB/OL. http:// www. ich. org/products/ctd, htmledition, 2006 -07 -01.
  • 2国家食品药品监督管理局.《关于按CTD格式撰写化学药品注册申报资料有关事项的通知》[EB/OL].http://www.sfda.gov.cn / WS01 / CL0844 / 54391.htnl,2010-09-25.
  • 3Guidance for industry. Container closure systems for packaging hu- man drugs and biologics [ EB/OL]. http://www, fda. gov/down- loads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances, 1999 - 05 - 01.
  • 4Guideline on plastic immediate packaging materials [ EB/OL]. ht- tp ://www. ema. europa, eu/ema/pages/includes/document, 2005 - 05 - 19.
  • 5Dennis J. Compatibility of pharmaceutical products and contact mate- rials published by John Wiley & Sons Inc, Hoboken, New Jersey, 2008.

共引文献1

同被引文献59

  • 1郑金旺.2020版欧盟GMP附录1草案的主要变化解读及对国内无菌产品生产的影响分析[J].化工与医药工程,2020,41(2):65-70. 被引量:6
  • 2龙再浩,马中春,陈小青.TTC原则在食品毒理学安全性评价中的应用[J].中国公共卫生,2006,22(8):959-961. 被引量:2
  • 3U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry. Container Closure Sys- tems for Packaging Human Drugs and Biologics [S ]. 1999.
  • 4国家食品药品监督管理局.化学药品注射剂与塑料包装材料相容性研究技术指导原则(试行)[S].2012.
  • 5EMEA. Guideline on Plastic Immediate Packaging Materials[ EB/ OL]. CPMP/QWWP/4359/03. EMEA/CVMP/205/04. 5/19/ 05. (2003). http ://www. ema. europa, eu/docs/en_ GB/docu- ment_library/Scientific guideline/2009/09/WC500003448, pdf.
  • 6KRUHLAK NL, CONTRERA JF, DANIEL BENZ R, et al. Mat- thews Progress in QSAR toxicity screening of pharmaceutical im- purities and other FDA regulated products [ J ]. Adv Drug Deliv Rev,2007, 59(1) : 43 -55.
  • 7JENKE D. Compatibility of Pharmaceutical Products and Contact Materials[ M]. Hoboken, New Jersey, USA: John Wiley & Sons, Inc. ,2008 : 32- 39.
  • 8EPT. 0. 3.1.6 polypropylene for containers and closures for par- enteral preparations and ophthalmic preparations [ S ]. 2010.
  • 9European Medicines Agency. Guideline on the specification limits for residues of metal catalysts or metal reagents[ S]. 2008.
  • 10PIRINGER OG, BANER AL. Plastic PackagingInteractions with Food and Pharmaceuticals[ M ]. 2nd Ed. Germany : WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim,2008:592 -598.

引证文献4

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部